Klivira
Request demo

Navigating Aetna Auvelity Prior Authorization Requirements

Efficiently managing Aetna Auvelity prior authorization is critical for patient access and revenue cycle stability. Klivira automates the complex workflows associated with securing approvals for this high-volume medication.

For revenue cycle directors and prior authorization teams, navigating specific payer requirements for high-volume medications like Auvelity presents significant operational challenges. Understanding Aetna's distinct submission channels, utilization management criteria, and appeal processes is key to minimizing denials and accelerating patient access to care.

Auvelity and Aetna's Pharmacy Benefit

Auvelity (dextromethorphan-bupropion) is an oral antidepressant approved for Major Depressive Disorder (MDD). As an outpatient prescription, Auvelity typically falls under Aetna's pharmacy benefit, administered by CVS Caremark, Aetna's pharmacy benefit manager since the 2018 CVS Health acquisition. This distinction dictates the primary prior authorization submission pathways and applicable utilization management criteria.

Key Submission Pathways for Auvelity PA with Aetna

  • **ePA Platforms:** For retail pharmacy claims, prior authorization requests for Auvelity can be submitted electronically via Aetna's ePA partners, CoverMyMeds or Surescripts.
  • **CVS Caremark Provider Portal:** For mail-order prescriptions or case-managed scenarios, direct submission through the CVS Caremark provider portal is often required.
  • **X12 278 Transactions:** While Aetna supports X12 278 transactions for medical benefit precertifications, pharmacy benefit prior authorizations like those for Auvelity primarily route through ePA partners or the PBM portal.

Aetna Utilization Management Criteria for Auvelity

Aetna's medical necessity criteria for pharmacy-benefit drugs, including Auvelity, are detailed within their Clinical Policy Bulletins (CPBs). These CPBs outline specific indications, step therapy requirements, and quantity limits. Providers must ensure documentation fully supports the criteria cited in the relevant CPB, which are published in the public Aetna CPB library.

Understanding Aetna Auvelity PA Turnaround Times

Prior authorization decision timeframes for Auvelity with Aetna vary by line of business and state regulations. Commercial plans generally adhere to state-mandated minimums and NCQA Utilization Management accreditation standards. For Medicare Advantage and Medicaid managed care plans (Aetna Better Health), CMS-0057-F mandates 72-hour standard and 24-hour expedited decision windows, with phased compliance timelines.

Common Denial Reasons and Appeal Pathways for Auvelity

Denials for Auvelity prior authorizations often stem from insufficient documentation of medical necessity, failure to meet step therapy requirements, off-label use without compendium support, or benefit exclusion. Aetna returns denial reasons via X12 835/277 transactions or portal updates, using standard CARC and RARC vocabularies. Aetna provides structured appeal pathways, typically including reconsideration, peer-to-peer review, and formal appeals, with expedited options for urgent cases.

Frequently asked questions

Which Aetna entity handles Auvelity prior authorizations?

Auvelity, as an outpatient oral medication, is typically managed under Aetna's pharmacy benefit. Prior authorizations are therefore handled by CVS Caremark, Aetna's pharmacy benefit manager, rather than through Aetna's medical benefit channels.

What are the primary electronic submission channels for Auvelity PA with Aetna?

For retail pharmacy prescriptions, Aetna facilitates electronic prior authorization (ePA) for Auvelity through established platforms like CoverMyMeds and Surescripts. For mail-order or specific case-managed scenarios, the CVS Caremark direct provider portal is often the designated channel.

Where can I find Aetna's medical necessity criteria for Auvelity?

Aetna publishes its utilization management criteria, including those for pharmacy-benefit medications like Auvelity, within its Clinical Policy Bulletins (CPBs). These CPBs are accessible in the public Aetna CPB library and detail specific indications, step therapy protocols, and quantity limits.

Does Aetna require step therapy for Auvelity?

Aetna publishes step-therapy protocols within applicable Clinical Policy Bulletins (CPBs) rather than in a separate central registry. Providers should consult the specific CPB for Auvelity to understand any prerequisite therapies or alternative medications that must be tried and failed before Auvelity is covered.

How do CMS-0057-F regulations impact Auvelity prior authorizations with Aetna?

CMS-0057-F directly impacts Aetna's Medicare Advantage and Medicaid managed care plans (Aetna Better Health), mandating specific decision timeframes (72 hours standard, 24 hours expedited) for prior authorization requests, including those for medications like Auvelity. This rule does not directly apply to Aetna's commercial lines of business.

Related coverage

Other auvelity prior authorization by payer

Other auvelity prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo